Cargando…

Reply: Possible Alternate Explanation for Cases of Idiopathic Pulmonary Fibrosis

Detalles Bibliográficos
Autores principales:	Kaul, Bhavika, Lee, Joyce S., Collard, Harold R., Whooley, Mary A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169133/ https://www.ncbi.nlm.nih.gov/pubmed/35289737 http://dx.doi.org/10.1513/AnnalsATS.202203-196LE

Ejemplares similares

Possible Alternate Explanation for Cases of Idiopathic Pulmonary Fibrosis
por: Frank, Arthur L.
Publicado: (2022)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Lee, Joyce S., et al.
Publicado: (2013)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Lee, Joyce S., et al.
Publicado: (2018)

Disparities in Rural Populations With Idiopathic Pulmonary Fibrosis
por: DeDent, Alison M., et al.
Publicado: (2022)

Epidemiology of idiopathic pulmonary fibrosis
por: Ley, Brett, et al.
Publicado: (2013)

Staging of idiopathic pulmonary fibrosis: past, present and future
por: Kolb, Martin, et al.
Publicado: (2014)

Models of disease behavior in idiopathic pulmonary fibrosis
por: Johannson, Kerri A., et al.
Publicado: (2015)

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management
por: Oldham, Justin M., et al.
Publicado: (2017)

4569 Burden of illness in idiopathic pulmonary fibrosis: A real-world cohort
por: Farrand, Erica, et al.
Publicado: (2020)

3541 The association of corticosteroid use with inpatient mortality in acute exacerbation of idiopathic pulmonary fibrosis
por: Farrand, Erica, et al.
Publicado: (2019)

Cleaved cytokeratin-18 is a mechanistically informative biomarker in idiopathic pulmonary fibrosis
por: Cha, Seung-Ick, et al.
Publicado: (2012)

Recent advances in the genetics of idiopathic pulmonary fibrosis
por: Spagnolo, Paolo, et al.
Publicado: (2023)

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials
por: Collard, Harold R, et al.
Publicado: (2013)

Variability in Global Prevalence of Interstitial Lung Disease
por: Kaul, Bhavika, et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis associated with pulmonary vein thrombosis: a case report
por: Cavaco, Raquel A, et al.
Publicado: (2009)

Potential Delays in Diagnosis of Idiopathic Pulmonary Fibrosis in Medicare Beneficiaries
por: Mooney, Joshua, et al.
Publicado: (2019)

Reply: Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control
por: Porter, Joanna C., et al.
Publicado: (2022)

How many patients with idiopathic pulmonary fibrosis are there in Brazil?
por: Baddini-Martinez, José, et al.
Publicado: (2015)

Economic consequences of idiopathic pulmonary fibrosis in Denmark
por: Hilberg, Ole, et al.
Publicado: (2018)

Reply to Kuśmierz and Toyoizumi: A network-based explanation of why most COVID-19 infection curves are linear
por: Thurner, Stefan, et al.
Publicado: (2021)

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
por: Maher, Toby M., et al.
Publicado: (2019)

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
por: Costabel, Ulrich, et al.
Publicado: (2019)

Myelodysplastic syndromes and idiopathic pulmonary fibrosis: a dangerous liaison
por: Papiris, Spyros A., et al.
Publicado: (2019)

Monocyte as a prognostic marker in patients with idiopathic pulmonary fibrosis
por: Zhu, Shiping
Publicado: (2021)

Genetic overlap between idiopathic pulmonary fibrosis and COVID−19
por: Allen, Richard J, et al.
Publicado: (2022)

The Possible Pathogenesis of Idiopathic Pulmonary Fibrosis considering MUC5B
por: Zhang, Qinghua, et al.
Publicado: (2019)

Pulmonary arterial hypertension preceding idiopathic pulmonary fibrosis in a BMPR2 mutation positive patient
por: Raamsteeboers, Aniek J., et al.
Publicado: (2014)

Comment on Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults
por: Scholand, Mary Beth, et al.
Publicado: (2022)

Coronavirus disease 2019 pneumonia may present as an acute exacerbation of idiopathic pulmonary fibrosis
por: Lee, Yong Hoon, et al.
Publicado: (2020)

The Systematic Removal of Participants Post-Randomization Can Lead to Alternate Explanations of the Results
por: Cunningham, John A
Publicado: (2013)

Reply to Moran-Mendoza: Idiopathic Pulmonary Fibrosis Update. Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?
por: Raghu, Ganesh, et al.
Publicado: (2022)

Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis
por: Molyneaux, Philip L., et al.
Publicado: (2017)

Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis
por: de Brouwer, Bart, et al.
Publicado: (2018)

Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience
por: Mullerpattan, Jai B, et al.
Publicado: (2019)

The world is not enough – the value of increasing registry data in idiopathic pulmonary fibrosis
por: Moor, C. C., et al.
Publicado: (2020)

Idiopathic pulmonary fibrosis mortality in the Italian epicenter of COVID-19 pandemic
por: Faverio, P., et al.
Publicado: (2023)

Thoracic ultrasound: Possible complementary criteria for the assessment of pulmonary fibrosis
por: Trovato, Guglielmo M., et al.
Publicado: (2014)

Idiopathic pulmonary fibrosis
por: Meltzer, Eric B, et al.
Publicado: (2008)

Idiopathic Pulmonary Fibrosis
por: Lynch, Joseph P., et al.
Publicado: (2011)

Alternative explanations of the Eötvös results
por: Fischbach, E, et al.
Publicado: (1986)

Cannot write session to /tmp/vufind_sessions/sess_j2f5dmusn5q7usbisoi9a5bf4e